Table 2 Multivariate analysis for PFS and OS
Model 1 | Model 2 | |||||
|---|---|---|---|---|---|---|
Variables | HR | 95% CI | p value | HR | 95% CI | p value |
Progression-free survival | ||||||
At least one previous line of treatment (versus 0 line) | 0.8 | 0.4–1.9 | 0.6 | 0.8 | 0.3–1.7 | 0.5 |
Elevated baseline LDH (versus normal) | 0.9 | 0.4–1.9 | 0.8 | 0.7 | 0.3–1.4 | 0.3 |
Diameter of the largest metastasis according to TNM (M1b/c versus M1a) | 1.0 | 0.4–2.5 | 1.0 | 0.8 | 0.3–1.9 | 0.6 |
ctDNA detection at baseline (versus negative) | 2.5 | 1.1–5.9 | 0.04 | / | / | / |
ctDNA clearance at 12w (versus negative at baseline and 12w) | ||||||
Yes | / | / | / | 1.7 | 0.6–4.8 | 0.3 |
No | / | / | / | 5.8 | 2.1–16.5 | 0.0009 |
Overall survival | ||||||
At least one previous line of treatment (versus 0 line) | 0.6 | 0.4-1.9 | 0.4 | 0.6 | 0.2–1.7 | 0.3 |
Elevated baseline LDH (versus normal) | 4.4 | 1.5–13.4 | 0.008 | 2.1 | 0.7–6.2 | 0.2 |
Diameter of the largest metastasis according to TNM (M1b/c versus M1a) | 0.8 | 0.2-2.5 | 0.7 | 0.9 | 0.3–2.6 | 0.8 |
ctDNA detection at baseline (versus negative) | 9.3 | 1.9–45.2 | 0.006 | / | / | / |
ctDNA clearance at 12w (versus negative at baseline and 12w) | ||||||
Yes | / | / | / | 6.8 | 0.7–69.2 | 0.1 |
No | / | / | / | 49.6 | 4.5–544.5 | 0.001 |
